Celgene Corporation (CELG) Earns “Neutral” Rating from BTIG Research

BTIG Research reiterated their neutral rating on shares of Celgene Corporation (NASDAQ:CELG) in a report released on Tuesday, September 5th.

Other analysts have also issued reports about the stock. Jefferies Group LLC set a $154.00 price objective on shares of Celgene Corporation and gave the stock a buy rating in a report on Saturday, May 13th. Vetr lowered shares of Celgene Corporation from a strong-buy rating to a buy rating and set a $132.90 target price for the company. in a report on Thursday, May 11th. Canaccord Genuity set a $156.00 target price on shares of Celgene Corporation and gave the company a buy rating in a report on Tuesday, June 6th. Mizuho lifted their target price on shares of Celgene Corporation from $130.00 to $134.00 and gave the company a buy rating in a report on Thursday, June 1st. Finally, J P Morgan Chase & Co reiterated a buy rating on shares of Celgene Corporation in a report on Wednesday, May 24th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and twenty-two have issued a buy rating to the stock. The stock presently has an average rating of Buy and an average price target of $147.31.

Celgene Corporation (CELG) opened at 142.07 on Tuesday. The stock has a 50 day moving average price of $134.40 and a 200-day moving average price of $126.94. Celgene Corporation has a 52 week low of $96.93 and a 52 week high of $142.64. The firm has a market capitalization of $111.15 billion, a P/E ratio of 44.00 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The business had revenue of $3.27 billion during the quarter, compared to analyst estimates of $3.23 billion. During the same period last year, the business posted $1.44 earnings per share. Celgene Corporation’s quarterly revenue was up 18.7% compared to the same quarter last year. Analysts anticipate that Celgene Corporation will post $7.32 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Celgene Corporation (CELG) Earns “Neutral” Rating from BTIG Research” was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://ledgergazette.com/2017/09/13/celgene-corporation-celg-receives-neutral-rating-from-btig-research.html.

In related news, Director Michael D. Casey sold 9,250 shares of Celgene Corporation stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $139.03, for a total transaction of $1,286,027.50. Following the transaction, the director now owns 9,250 shares in the company, valued at approximately $1,286,027.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Robert J. Hugin sold 175,970 shares of Celgene Corporation stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $134.14, for a total transaction of $23,604,615.80. Following the transaction, the insider now owns 1,033,909 shares in the company, valued at approximately $138,688,553.26. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 263,011 shares of company stock worth $35,078,473. 0.95% of the stock is owned by corporate insiders.

A number of hedge funds have recently made changes to their positions in CELG. Patten & Patten Inc. TN lifted its stake in Celgene Corporation by 0.4% in the 1st quarter. Patten & Patten Inc. TN now owns 43,332 shares of the biopharmaceutical company’s stock worth $5,392,000 after purchasing an additional 157 shares in the last quarter. WealthTrust Arizona LLC increased its holdings in shares of Celgene Corporation by 26.1% in the 1st quarter. WealthTrust Arizona LLC now owns 1,213 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 251 shares during the last quarter. Barometer Capital Management Inc. increased its holdings in shares of Celgene Corporation by 722.2% in the 1st quarter. Barometer Capital Management Inc. now owns 44,400 shares of the biopharmaceutical company’s stock worth $5,525,000 after buying an additional 39,000 shares during the last quarter. Lederer & Associates Investment Counsel CA increased its holdings in shares of Celgene Corporation by 4.7% in the 1st quarter. Lederer & Associates Investment Counsel CA now owns 15,055 shares of the biopharmaceutical company’s stock worth $1,873,000 after buying an additional 680 shares during the last quarter. Finally, Alta Capital Management LLC increased its holdings in shares of Celgene Corporation by 36.2% in the 1st quarter. Alta Capital Management LLC now owns 380,331 shares of the biopharmaceutical company’s stock worth $47,324,000 after buying an additional 101,113 shares during the last quarter. Institutional investors and hedge funds own 79.43% of the company’s stock.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply